ProCE Banner Activity


Investigational PPAR-delta Agonist for PBC Treatment and Race-based Considerations for PBC Diagnosis: Conference Coverage of AASLD

Conference Coverage
Clinical Thought

Read my take on new primary biliary cholangitis (PBC) data from AASLD 2023, including a study of an investigational second-line agent—a PPAR-delta agonist—and data on differences in clinical presentation between Black and White patients with PBC and how this may impact diagnosis.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 06, 2023

Expiration: December 05, 2024



Stuart Gordon

Stuart Gordon, MD, FAASLD

Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from CymaBay Therapeutics.

CymaBay Therapeutics

Target Audience

This program is intended for physicians and other HCPs involved in the care of patients with PBC.

Program Learning Goal

The goal of this activity is to improve learners’ competence in translating the most clinically significant data from AASLD 2023 into practical management strategies for patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate the results of recent clinical studies of PBC screening and management into clinical practice

  • Describe emerging agents for PBC, including mechanism of action, clinical data for both biochemical and symptom response, safety, and potential place in therapy


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Stuart Gordon, MD, FAASLD

Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Stuart C. Gordon, MD, FAASLD: researcher (paid to institution): AbbVie, Arbutus, CymaBay, DURECT, Eiger, Enanta, Gilead Sciences, GlaxoSmithKline, Hightide, Intercept, Ipsen, Mirum, Pliant; consultant: AbbVie, CymaBay, Gilead, GlaxsoSmithKline, Ipsen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 06, 2023, through December 05, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.